Citius Oncology will hold its annual stockholder meeting on September 29, with three Class II director seats and auditor ratification on the agenda. Stockholders recorded on August 17 can vote, making that Record Date central to participation in the company’s governance decisions.

Key Highlights

  • Wolf & Company, P.C. is proposed for ratification as Citius Oncology’s independent registered public accounting firm for the year ending September 30, 2026.
  • Stockholders recorded at the close of Business on August 17 are eligible to vote at the annual meeting.
  • In-person attendees must register by September 22 through Jaime Bartushak using the company’s Cranford, New Jersey address.

CITIUS ONCOLOGY, INC. (NASDAQ: CTOR) will hold its annual stockholder meeting on September 29, with three Class II director seats up for election.

Director Elections and Auditor Vote Set for September 29

The three Class II nominees would serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders will also vote on ratifying Wolf & Company, P.C. as the independent registered public accounting firm for the year ending September 30, 2026. Other business may be considered if it properly comes before the meeting or an adjournment.

Citius Oncology urged stockholders to vote by proxy whether or not they attend in person.

The record date is August 17. Shareholders planning to attend in person must register with Jaime Bartushak by September 22 through email, telephone or mail at the Cranford headquarters. Holders whose shares are registered through a broker, bank or nominee must obtain a proxy in their name to vote at the meeting.

The proxy materials also describe the company’s executive compensation process. The Compensation Committee reviews corporate and individual performance and may use FW Cook, an independent executive compensation adviser, in setting compensation policies for fiscal 2027.

Peers Moving on This News

  • OS Therapies Incorporated (AMEX: OSTX) up 0.6%
  • Forum Markets, Incorporated (NASDAQ: FRMM) up 3.5%
  • Cardiff Oncology, Inc. (NASDAQ: CRDF) up 0.4%

Source(s)

  • https://www.sec.gov/Archives/edgar/data/1851484/000121390026093757/ea0302414-def14a_citius.htm